Molecular pharmacology therapeutics

The Serotonin Receptors From Molecular Pharmacology To Human Therapeutics, edited by Bryan L. Roth, 2006... 

Krogsgaard-Larsen, P., Frplund, B., and Frydenvang, K. (2000) GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr. Pharm. Des. 6, 1193-1209. 

Molecular Pharmacology of Alzheimer s Disease with Novel Therapeutic Strategies... 

P. Krogsgaard-Larsen, P. Jacobsen, E. Falch, H. Hjeds (1982). GABA-agonists chemical, molecular, pharmacologic and therapeutic aspects. In A. M. Creighton, S. Turner (Eds.). The Chemical Regulation of Biological Mechanisms. London Royal Society of Chemistry. 

Molecular pharmacology and therapeutic potential of thromboxane A2 receptor antagonists, 25, 173... 

From Molecular Pharmacology to Human Therapeutics Edited by B. L. Roth Humana Press Inc., Totowa, NJ... 

To develop highly potent, selective, and efficacious delta agonists of potential therapeutic value, the Molecular Pharmacology Department at AstraZeneca R D Montreal has established and implemented binding and functional assays for all three human opioid receptors [11]. These assays were used to provide in vitro pharmacological data to support the design, synthesis, and analysis of newer generations of delta selective compounds. In the... 

Biopharmaceuticals represent a broad but discrete class of large molecular weight therapeutic entities that are characterized by their specific pharmacological activities and distinctive pharmacokinetics. The selection of an appropriate animal model is dependent on a combination of PD and PK factors. As described in this chapter, it is essential to understand the relationship of the basic pharmacology of a biopharmaceutical (signaling, receptor presence, binding properties, etc.) and the associated PK properties to that expected in humans, in order to select animal species that will have the most predictive value in safety assessments. 

The effects of cannabinoids are due to an interaction with high affinity specific receptors present in the central nervous system (Devane et al.. Molecular Pharmacology (1988) 34, 605-613) and peripheral nervous system (Nye et al.. The Journal of Pharmacology and Experimental Therapeutics (1985) 234, 784-791 30 Kaminski et al.. Molecular Pharmacology (1992) 42, 736-742 Munro et at.. Nature (1993) 365, 61-65). 

Miscellaneous antirheumatic drugs and their possible modes of action, 11. 1 Molecular aspects of the storage and uptake of catecholamines. 6. 121 Molecular mechanisms of specificity in DNA-antitumour drug interactions, 18, 1 Molecular pharmacology and therapeutic potential of thromboxane A receptor antagonists. 

---